Last reviewed · How we verify
Placebo for SCH 900962
This is a placebo control with no active pharmacological mechanism.
At a glance
| Generic name | Placebo for SCH 900962 |
|---|---|
| Sponsor | Organon and Co |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo formulations contain no active pharmaceutical ingredient and serve as control comparators in clinical trials to establish the efficacy of the investigational drug SCH 900962 through blinded comparison. The placebo allows researchers to distinguish true drug effects from natural disease progression and psychological effects.
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy and Safety of a Single Injection of Corifollitropin Alfa (Organon 36286) for Ovarian Stimulation Using Daily Recombinant Follicle Stimulating Hormone (FSH) as Reference (P05787) (PHASE3)
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05690 (Care Program) (P05710)
- Efficacy and Safety Study of a Single Injection of SCH 900962 Versus Daily recFSH Injections in Women Undergoing Controlled Ovarian Stimulation (Study P06029) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for SCH 900962 CI brief — competitive landscape report
- Placebo for SCH 900962 updates RSS · CI watch RSS
- Organon and Co portfolio CI